secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kalaris Therapeutics, Inc. (KLRS)
CIK:        0001754068
Form:       8-K
Filed at:   2022-03-31T23:59:59+00:00
Accession:  0001193125-22-090667
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AlloVir appoints Shawn Tomasello to board; co-founder John Wilson to retire
---------------------------------------------------------------------------

- Shawn Tomasello appointed to Board of Directors effective March 29, 2022, serving as Class III director until 2023 annual meeting.
- John Wilson, co-founder and former executive director, will retire and not stand for re-election at 2022 annual meeting.
- Ms. Tomasello brings over 35 years of life sciences experience, with specific expertise in cell and gene therapy commercialization.
- Board determined Ms. Tomasello is independent under Nasdaq listing standards; she will receive standard non-employee director compensation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1754068/000119312522090667/0001193125-22-090667-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1754068/000119312522090667/d295737d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-090667

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer